Macimorelin Research: What 46 Studies Show (2026) | RetatrutideCompare

Macimorelin — 46 studies indexed on PubMed. Oral GHS-R1a agonist used as a single-dose diagnostic test for adult GH deficiency. Half-life: ~4 hours. FDA status: FDA-approved (2017).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Macimorelin?

There are approximately 46 studies indexed on PubMed that mention Macimorelin (Macrilen, AEZS-130), based on a search last updated 2026-06-18.

Is Macimorelin FDA-approved?

FDA status: FDA-approved (2017).

How does Macimorelin work?

Oral GHS-R1a agonist used as a single-dose diagnostic test for adult GH deficiency.

Oral GHS-R1a agonist used as a single-dose diagnostic test for adult GH deficiency.

Reference facts

Also known as
Macrilen, AEZS-130
Category
Growth Hormone & Ghrelin
Mechanism of action
Oral GHS-R1a agonist used as a single-dose diagnostic test for adult GH deficiency.
Targets
GHS-R1a
Indications under research or approved
Diagnosis of adult growth hormone deficiency
Regulatory status (reference entry)
FDA-approved (2017)
Half-life
~4 hours
Sequence notes
Orally active tripeptidomimetic ghrelin receptor agonist.
Molecular weight (Da)
535
Originator / sponsor
Aeterna Zentaris / Novo Nordisk
First reported
2013

Primary References

Explore research articles about Macimorelin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.